All fields are required.

Close Appointment form

BioServe Partners with Seegene

BioServe Partners with Seegene to Collaborate on the Development of New Detection System for Infectious Diseases in India

May 14, 2007

Combination of BioServe’s molecular diagnostics and genomics expertise and Seegene’s novel multiple pathogen detection technology to help fight the spread of Indian epidemics

Laurel, MD, May 14, 2007 – BioServe and Seegene today announced a partnership to develop, validate and service new test systems for a variety of infectious diseases in the Indian market

Through this partnership, Seegene will access BioServe’s large repository of Indian DNA samples to collaborate on developing test systems for a wide range of infectious illnesses, such as sexually transmitted diseases (STDs), Tuberculosis (TB) and Human immunodeficiency virus (HIV) (1 & 2). Under the terms of the agreement, BioServe will offer diagnostic testing services using Seegene’s Seeplex™ STD detection system for Mycoplasma hominis, Ureaplasma urealyticum, Neisseria gonorrhoeae, Chlamydia trachomatis, Herpes Simplex Virus 2 (HSV-2) and Human Papillomavirus (HPV). All of the test systems are based on Seegene’s novel DPO™ technology, the first DNA amplification method able to simultaneously and accurately detect multiple pathogens in a single test.

The infectious disease detection systems that BioServe and Seegene will develop for the Indian market have the potential to play a key role in the early detection of multiple pathogens ravaging the Indian population. India is experiencing rapid socio-economic progress and development, yet the country’s population suffers from a high prevalence of infectious disease. For example, according to World Health Organization statistics, India reports approximately 1.8 million of new cases of TB each year. In 2006, outbreaks of infectious diseases like dengue and chikungunya claimed lives approaching epidemic proportions. There are over 5.1 million Indians currently HIV-infected; South Africa is the only nation with more HIV-positive citizens.

“In a country where approximately 400,000 people die of TB each year, and more than 5,000 develop the disease each day, early detection and treatment are absolutely critical for the long-term health of the Indian nation,” said Kevin Krenitsky, BioServe’s Chief Executive Officer. “The combination of BioServe’s deep molecular diagnostics and genomics expertise and Seegene’s unique multiple pathogen test technology will result in important new tests in the fight against the spread of Indian epidemics.”

“Our Seeplex system enables front line healthcare workers to accurately test for a number of pathogens in a single test, fundamentally altering the speed and economics of disease detection,” said Jong-Yoon Chun, Seegene’s Chief Executive Officer. “Seegene is currently working with various international health organizations and major commercial reference laboratories in many different countries. BioServe’s large presence in India, featuring a state-of-the-art genomics facility, and molecular diagnostic experience is the strategic partner Seegene needs to further develop, validate and service new infectious disease test systems for the Indian market.”